scispace - formally typeset
P

Pierpaolo Di Micco

Researcher at Seconda Università degli Studi di Napoli

Publications -  126
Citations -  2057

Pierpaolo Di Micco is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Pulmonary embolism & Thrombophilia. The author has an hindex of 22, co-authored 124 publications receiving 1594 citations. Previous affiliations of Pierpaolo Di Micco include University of Naples Federico II.

Papers
More filters
Journal ArticleDOI

Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry.

TL;DR: This registry of consecutive patients with acute VTE tried to identify which cancer patients are at a higher risk for recurrent pulmonary embolism (PE), deep vein thrombosis (DVT) or major bleeding.
Journal ArticleDOI

Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry

TL;DR: Clinical factors predicting a fatal PE identified in this study, including cancer, immobility, comorbidities, increasing age, PE at presentation, could be considered for risk stratification scheme for secondary prophylaxis in daily practice.
Journal ArticleDOI

Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study.

TL;DR: Pre-admission antithrombotic therapy, both antiplatelet and anticoagulant, does not seem to show a protective effect in severe forms of COVID-19 with ARDS at presentation and rapidly evolving toward death.
Journal ArticleDOI

Venous thromboembolism during pregnancy, postpartum or during contraceptive use

TL;DR: The outcome of pregnant or postpartum women with VTE is similar to that in contraceptive users, even though the treatment is different, and the non-specific nature of PE signs may have caused some delay in PE diagnosis.
Journal ArticleDOI

Clotting factors in COVID-19: Epidemiological association and prognostic values in different clinical presentations in an Italian cohort

TL;DR: Fibrinogen seems to increase early in COVID-19 patients and may be used as a risk stratification marker for the early detection of a subgroup of CO VID-19 patient at increased risk to develop SARS, who might benefit from a different and thorough clinical surveillance and treatment.